"The rising use of GLP-1 drugs for type 2 diabetes and weight ... The first is one in which up to 20 million US adults are ...
More U.S. employers are covering GLP-1s for weight loss, according to a survey. Meanwhile, 25% of health-care VC dollars are ...
Semaglutide 2.4 mg weekly, assessed in 17,604 individuals with body mass index (BMI) ≥27 kg/m² and cardiovascular disease ...
New research has found that for people with extreme obesity taking GLP-1 drugs like Ozempic or Wegovy before bariatric ...
GLP-1 agonist prescriptions rose by nearly 600% among adolescents and young adults in the United States between 2020 and 2023.
In patients with type 2 diabetes, GLP-1 agonist therapy is associated with decreased risk for AF recurrence following ablation for AF.
Folks using a weight-loss drugs like Ozempic, Wegovy or Zepbound still have nutritional requirements for good health, even if ...
While GLP-1 drugs remain wildly popular and are a highly lucrative sector, data analytics firm GlobalData contends ...
With GLP-1s, providers must always be prepared for patients being forced to stop a medication due to factors beyond the ...
6,7 It is recommended to tell your physician about the medications you are taking before starting a GLP-1 receptor agonist. When taken with short-acting insulin ... best way to stop taking these ...
Talking about weight and weight loss with Johann Hari, an Ozempic user and the author of "Magic Pill: The Extraordinary ...
Analyzing Madrigal Pharmaceuticals' potential in the competitive NASH drug market and why it may be right for your portfolio.